4D Molecular Therapeutics Inc (NAS:FDMT)
$ 25.15 0 (0%) Market Cap: 1.30 Bil Enterprise Value: 788.60 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 57/100

4D Molecular Therapeutics Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) Transcript

May 30, 2023 / 08:45PM GMT
Release Date Price: $18.38 (+4.37%)
Dae Gon Ha
Stifel Financial - Analyst

Great. Good afternoon, everyone. Thanks for sticking with us for the last session of the day for our inaugural virtual genetic medicines day. Just a reminder, my name is Dae Gon Ha, one of the biotech analysts here at Stifel. (Conference Instructions)

But for now, the next 30 minutes, we're going to be discussing 4D Molecular. And from the company, we're going to be having both the CEO David Kirn; as well as a Chief Operating Officer and President, Fred Kamal.

So, David, I'll turn it over to you. David's got a couple of slides as an introductory remarks and then we'll dive into Q&A. So, David, thank you.

David Kirn
4D Molecular Therapeutics, Inc. - CEO & Co-Founder

All right. Thanks for having us. Welcome, everyone. We'll just introduce the company through a few key slides upfront. So we're 4D Molecular Therapeutics, FDMT. This is our pipeline. We have a number of sustainable, large market gene therapy product opportunities in our portfolio.

We have products in ophthalmology, lung,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot